Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02421315
Other study ID # 7006
Secondary ID R21MH101441
Status Completed
Phase N/A
First received
Last updated
Start date October 2014
Est. completion date September 30, 2021

Study information

Verified date August 2023
Source New York State Psychiatric Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to examine the brain functioning of children and adolescent with OCD before and after treatment with Exposure and Response Prevention (EXRP) therapy.


Description:

The capacity to coordinate thoughts and actions to execute goal-directed behaviors (cognitive control) and the capacity to anticipate, respond to, and learn from reward (reward processing) are key processes for human behavior. Dysfunction in these processes has been hypothesized to contribute to repetitive thoughts and behaviors in many disorders, including obsessive-compulsive disorder (OCD), Tourette Syndrome (TS), and eating disorders. The investigators will use multimodal imaging to investigate neural circuits that support cognitive control and reward processing, using pediatric OCD as a model system. The short-term goal is to clarify how circuit-based abnormalities contribute to repetitive thoughts/behaviors; these data will inform future trans-diagnostic studies. The long-term goal is to identify control and reward circuit-abnormalities as targets for new trans-diagnostic treatments.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date September 30, 2021
Est. primary completion date September 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Years to 17 Years
Eligibility Patient Inclusion Criteria: - Participants must be 5-17 at the time of consent - Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Diagnosis of OCD as the principal problem - Not on psychotropic medication and not receiving current psychotherapy for OCD - Written informed assent by the participants (8 and older) and consent by the parent - Participants and a parent/guardian must be able to read and understand English Patient Exclusion Criteria: - DSM-IV current diagnosis of major depressive disorder, attention-deficit hyperactivity disorder, Tourette's/Tic Disorder, or substance/alcohol abuse - DSM-IV lifetime diagnosis of psychotic disorder, bipolar disorder, eating disorder, pervasive developmental disorder, or substance/alcohol abuse - Active suicidal ideation - Females who are pregnant or nursing - Major medical or neurological problems - Presence of metallic device or dental braces - IQ<80 - A current or past diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS) - Individuals who are currently receiving CBT, other forms of psychotherapy, or psychotropic medications - Individuals who have received a full course of CBT in the past - A positive pregnancy test - Positive urine screen for illicit drugs - Inability of participant or parent/guardian to read or understand English Healthy Control Inclusion Criteria: - Participants must be 5-17 at the time of consent - Written informed assent by the participants (8 and older) and consent by the parent - Participants and a parent/guardian must be able to read and understand English Healthy Control Exclusion Criteria: - Any current or lifetime psychiatric diagnosis - Active suicidal ideation - Females who are pregnant or nursing - Major medical or neurological problems - Presence of metallic device or dental braces - IQ<80 - A current or past diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS) - A positive pregnancy test - Positive urine screen for illicit drugs - Inability of participant or parent/guardian to read or understand English

Study Design


Intervention

Behavioral:
CBT treatment for OCD based on Exposure & Response Prevention (EX/RP) and when indicated medication treatment
CBT treatment consisted of 12-16 hour-long sessions. For exceptional cases not showing clinical improvement after six CBT treatment sessions, complementary pharmacological treatment (SSRI) was offered as part of our treatment protocol. CBT for OCD involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.

Locations

Country Name City State
United States NY State Psychiatric Institute New York New York

Sponsors (2)

Lead Sponsor Collaborator
New York State Psychiatric Institute National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brain Activation Associated With the Resolution of Cognitive Conflict Task-based functional magnetic resonance imaging (fMRI) will be acquired from children and adolescents diagnosed with OCD and healthy comparison subjects (HCs) during their performance of a Simon Spatial Compatibility Task.
In each trial, participants are presented with a leftward or rightward pointing arrow that is either congruent or incongruent with their position (left or right) on the screen. Participants are instructed to respond as quickly and accurately as possible to the direction in which the arrow was pointing by pressing a button on a response box using the index finger for left and the middle finger for right. Brain activation during the resolution of cognitive conflict is computed by contrasting blood-oxygen-level-dependent (BOLD) signal during Incongruent versus Congruent trials. BOLD signal is expressed in arbitrary units (A.U.s).
single time point: baseline
Secondary Functional Connectivity Functional magnetic resonance imaging (fMRI) will be acquired from children and adolescents diagnosed with OCD and healthy comparison subjects (HCs) at baseline and after approximately 16-20 weeks (i.e., post-treatment for the participants with OCD). The whole brain is divided in 352 brain regions comprised of 333 cortical surface (Gordon et al. Cereb Cortex 2016;26:288-303) and 19 subcortical (Fischl et al. Neuron 2002;53:341-55) parcellated regions. FC-strength (average of Fisher-r-to-Z transformed Pearson correlation coefficients) between each region was computed.
Values >0 indicate regions are positively connected (synchronized), with larger values indicating stronger connection. Values <0 indicate regions are negatively connected (inversely synchronized), with more negative values stronger negative connection. A value of 0 indicates that the regions are not connected.
single time point: Baseline
Secondary Brain Gray Matter Thickness Structural MRI will be acquired from children and adolescents diagnosed with OCD and healthy comparison subjects (HCs). Regional cortical thickness will be computed in the inferior frontal gyrus Single time point: Baseline
Secondary Structural Connectivity (Streamline Counts) Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI) will be acquired from children and adolescents diagnosed with OCD and healthy comparison subjects (HCs). A structural connectivity matrix is estimated for each participant using the standard MRtrix3 preprocessing pipeline, yielding 164x164 symmetrical streamline count matrix for each participant using the FreeSurfer segmentations/parcellations noted above (148 cortical, 14 subcortical regions, and the left and right cerebellum). Using this approach, streamline count between brain regions is proportional to the cross-sectional area of white matter fibers connecting those regions. Thus, streamline count is a biologically plausible metric of "structural connectivity" proposed to represent the communication 'bandwidth' between regions. Single time point (baseline)
See also
  Status Clinical Trial Phase
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Completed NCT02855580 - Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
Completed NCT02229903 - An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD N/A
Completed NCT02202915 - CBT for Pediatric OCD: Community Training Pilot N/A
Completed NCT01794156 - Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder N/A
Completed NCT02089984 - Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders N/A
Completed NCT01348529 - Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT00965211 - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome N/A
Not yet recruiting NCT00743834 - Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Phase 4
Completed NCT01172873 - D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD N/A
Completed NCT00723060 - Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Phase 4
Completed NCT01981317 - Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder N/A
Completed NCT02194075 - Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Phase 4
Completed NCT01686087 - Attaining and Maintaining Wellness in Obsessive-compulsive Disorder N/A
Terminated NCT00997087 - A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder Phase 2
Completed NCT01331876 - Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy N/A
Completed NCT00533806 - Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder Phase 3
Completed NCT00517244 - Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders N/A
Completed NCT00169377 - Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD) Phase 1/Phase 2
Completed NCT00116532 - Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) Phase 4